ZLAB vs CAN vs LEGN vs MARA

For growth investors, Canaan Inc.

(CAN) is the stronger pick with 96. 7% revenue growth year-over-year, versus 15. 3% for Zai Lab Limited (ZLAB). Analysts rate Zai Lab Limited (ZLAB) a "Buy" — based on 11 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Legend Biotech Corporation (LEGN) delivered a total return of -0.

0%, compared to -92. 3% for Canaan Inc. (CAN). Over 10 years, the gap is even starker: LEGN returned -22. 8% versus CAN's -90. 1%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Legend Biotech Corporation (LEGN) is the lower-risk stock at 0.

77β versus Canaan Inc. 's 4. 41β — meaning CAN is approximately 475% more volatile than LEGN relative to the S&P 500. On balance sheet safety, Canaan Inc. (CAN) carries a lower debt/equity ratio of 13% versus 105% for Marathon Digital Holdings, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Canaan Inc.

(CAN) is pulling ahead at 96. 7% versus 15. 3% for Zai Lab Limited (ZLAB). On earnings-per-share growth, the picture is similar: Canaan Inc. grew EPS 51. 1% year-over-year, compared to -314. 5% for Marathon Digital Holdings, Inc.. Over a 3-year CAGR, LEGN leads at 106. 6% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Legend Biotech Corporation (LEGN) is the more profitable company, earning -28.

8% net margin versus -144. 6% for Marathon Digital Holdings, Inc. — meaning it keeps -28. 8% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: LEGN leads at -13. 3% versus -90. 6% for MARA. At the gross margin level — before operating expenses — LEGN leads at 60. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for CAN: 336.

9% to $2. 25.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Legend Biotech Corporation (LEGN) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

77)). Canaan Inc. (CAN) carries a higher beta of 4. 41 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (LEGN: -22. 8%, CAN: -90. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (ZLAB (Healthcare) and CAN (Technology) and LEGN (Healthcare) and MARA (Financial Services)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.